Table 3.
Estimated Parameters According to Anti-Hepatitis C Virus Serology
| Anti-HCV (+) N | Anti-HCV (−) N | p | |
|---|---|---|---|
| Women | 15 (62,5) | 9 (37,5) | >0.05 |
| Men | 25 (59,5) | 17 (40,5) | |
| Intravenous drug usage | 35 (97,2) | 1 (2,8) | <0.0001 |
| Sexual route | 5 (16,7) | 25 (83,3) | |
| eGFR >90 (ml/min) | 29 (60,4) | 19 (39,6) | >0.05 |
| eGRF ≤90 (ml/min) | 11(61,1) | 7 (38,9) | |
| HIV viremia <50 (copies/ml) | 35 (59,3) | 24 (40,7) | >0.05 |
| HIV viremia ≥50 (copies/ml) | 5 (71,4) | 2 (28,6) | |
| PIs | 33 (71,7) | 13 (28,3) | =0.005 |
| NNRTI | 7 (35,0) | 13 (65,0) | |
| Median (LQ-UQ) | Median (LQ-UQ) | ||
| Age (years) | 34.5 (32.5–40) | 45 (36–51) | =0.0016 |
| Years on present treatment scheme | 3 (2–4) | 3 (1–5) | >0.05 |
| Years on cART | 5 (4–8.5) | 4 (2–8) | >0.05 |
| CD4 lymphocytes (cells/μl) | 475 (315.5–646) | 428 (270–512) | >0.05 |
| ALT (U/liter) | 46.5 (22.5–70) | 24.5 (16–33) | =0.0012 |
| Creatinine (mg/dl) | 0.86 (0.76–0.95) | 0.82 (0.68–0.93) | >0.05 |
| Weight (kg) | 71 (77–60) | 75 (85–64) | >0.05 |
| eGFR (ml/min) | 97.68 (87.86–114.69) | 103.41 (88.53–117.25) | >0.05 |
| KIM-1 (μg/g creatinine) | 0.93 (0.57–1.98) | 1.018 (0.5–1.62) | >0.05 |
| L-FABP (μg/g creatinine) | 0.77 (0–5.60) | 0.71 (0–3.67) | >0.05 |
| L-FABP/KIM-1 | 0.52 (0–5.85) | 0.71 (0–2.10) | >0.05 |
eGFR (estimated glomerular filtration rate; MDRD formula); HCV, hepatitis C virus; PIs, protease inhibitors; NNRTI, nonnucleoside reverse transcriptase inhibitor; cART, combined antiretroviral therapy; ALT, alanine aminotransferase; KIM-1, kidney injury molecule-1; L-FABP, liver-type fatty acid-binding protein.